News and Events


November 1, 2017

The 9th International Patient Symposium on Myeloproliferative Neoplasms, presented by the Cancer Research & Treatment Fund (CR&T), will be held on Wednesday, November 1 at Weill Cornell Medical College in New York City. Patients and their families who attend this full-day event will learn about the latest advances in research developments and treatment, and participate in disease-specific Q&A sessions. This is a unique opportunity to engage with distinguished MPN researchers and physicians from the world’s leading cancer centers.
Spaces are limited. For details and to register online, click here, or call CR&T at 212-288-6604.

MPN Advocacy & Education International Calendar of Events

Click here to view the MPN Advocacy & Education International Calendar of Events

Events range from January to June, 2017


June 6, 2016

5 year Results from the Phase 3 Study of Jakafi

Living with MPNs Survey

A 30-minute survey for patients with myeloproliferative neoplasms (MPNs). A research study (sponsored by Incyte Corporation) is being conducted to learn more about the impact of MPNs on patients' lives. Incyte is seeking patients aged 18 to 70 with MF, PV or ET to participate in a one-time, 30-minute online survey about how your condition has affected your work, finances, and quality of life. If you are eligible and complete the survey, you will be compensated.For more information, please visit []

FDA approval of Jakafi (Ruxolitnib) for the treatment of Polycythemia Vera


We are pleased to announce the theme for our Fourth Annual MPN Heroes Recognition Program®, Recognizing the Unsung Hero: Reaching Underserved Communities!

This year’s theme asks nominators to consider individuals or organizations who have significantly contributed to providing services and medical care to underserved MPN populations or who are dedicated to meeting the health care needs of medically underserved* MPN patients. The 2016 theme is an excellent way to bring awareness to the needs of underserved MPN patients and highlight some of the great work being done to address these needs throughout the country.

Please note that nominations are not limited to those who have an impact on underserved MPN patient communities; rather, the theme is meant to promote variation among nominations.

You can nominate a Hero through any of the following ways:

Nominations will close on September 8, 2016 and recipients will be celebrated at a dinner in December 2016 in San Diego, CA.

For more information, please visit the MPN Heroes™ Recognition Program page ( on the Voices of MPN website (

*MPN Heroes is a program developed by Incyte Corporation, in collaboration with CURE Media Group, publishers of CURE magazine. Recognition recipients are chosen by an independent panel of judges of doctors, nurses, patients and patient advocates from the MPN community.

National Organization of Rare Diseases

Stories about 3 patients (Antje with ET, Annette with PV and Bill with MF) on the NORD website:


The MPD Research Consortium is a National Cancer Institute supported project involving 50 International MPN Centers in the United States, Canada, Europe and Israel. It is a resource for both patients and physicians focusing on advancing the science and therapy of myeloproliferative neoplasms

Are You a Vietnam Veteran?

Were you exposed to Agent Orange? Do You Have Myelofibrosis (MF), Polycythemia Vera (PV) or Essential Thrombocythemia (ET)?

MPN Advocacy and Education International is conducting a survey of Vietnam Veterans to determine how many were exposed to Agent Orange and now have a diagnosis of Myelofibrosis, Polycythemia Vera, or Essential Thrombocythemia (Myeloproliferative Neoplasms- MPNs. This information will be collected in an attempt to add myeloproliferative neoplasms to the US Department of Veterans Affairs 'presumptive' list of conditions resulting from exposure to Agent Orange/dioxin during the Vietnam War and could create a resource for assistance with treatments and compensation.

This is our first step in what could allow for further research into the link between myeloprliferative neoplasms and exposure to Agent Orange/dioxin.

Please contact Ann Brazeau: